Statin-associated adverse effects beyond muscle and liver toxicity

Atherosclerosis

Volumn 195, Issue 1, 2007, Pages 7-16

  Kiortsis, D N ^a   Filippatos, T D ^a   Mikhailidis, D P ^b   Elisaf, M S ^a   Liberopoulos, E N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adverse effects; Cancer; HMG CoA reductase inhibitors; Myopathy; Neuropathy; Renal effects; Side effects; Statins

Indexed keywords

ABCIXIMAB; ATORVASTATIN; CERIVASTATIN; COLESTIPOL; COLESTYRAMINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GADOLINIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; MEVALONIC ACID; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; ALLERGIC PNEUMONITIS; AMNESIA; ANXIETY; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CANCER; CARDIOVASCULAR DISEASE; CATARACT; CHEILITIS; CHOLELITHIASIS; CHOLESTASIS; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DERMATOMYOSITIS; DIARRHEA; DRUG EFFECT; DRUG MEGADOSE; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; FLATULENCE; GUILLAIN BARRE SYNDROME; GYNECOMASTIA; HEPATITIS; HUMAN; INSOMNIA; INTERSTITIAL PNEUMONIA; INTRAOCULAR HEMORRHAGE; LIBIDO DISORDER; LICHENOID ERUPTION; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; META ANALYSIS; MIGRAINE; MONOTHERAPY; MORBIDITY; MORTALITY; MUSCLE INJURY; NAUSEA; NEPHROTOXICITY; NIGHTMARE; NOSE POLYP; OBSTRUCTIVE JAUNDICE; PANCREATITIS; PERIPHERAL NEUROPATHY; POLYMYOSITIS; PRIORITY JOURNAL; PROTEINURIA; PURPURA; RASH; REVIEW; SENSE ORGAN; SIDE EFFECT; SLEEP DISORDER; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 35248885161     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.10.001     Document Type: Review

References (122)

1. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
3. Athyros V.G., Papageorgiou A.A., Mercouris B.R., et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18 (2002) 220-228
4. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
5. Newman C.B., Palmer G., Silbershatz H., and Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients. Am J Cardiol 92 (2003) 670-676
6. Pasternak R.C., Smith S.C., Bairey-Merz C.N., et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 33 (2002) 2337-2341
7. Jones P., Kafonek S., Laurora I., and Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81 (1998) 582-587
8. Ballantyne C.M., Blazing M.A., Hunninghake D.B., et al. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). Am Heart J 146 (2003) 862-869
9. El-Hajj I.I., Mourad F.H., Shabb N.S., and Barada K.A. Atorvastatin-induced severe gastric ulceration: a case report. World J Gastroenterol 11 (2005) 3159-3160
10. Batey R.G., and Harvey M. Cholestasis associated with the use of pravastatin sodium. Med J Aust 176 (2002) 561
11. Yoshida E.M., and Levin A. Lovastatin and cholestasis. CMAJ 148 (1993) 374
12. Rea W.E., Durrant D.C., and Boldy D.A. Ulcerative colitis after statin treatment. Postgrad Med J 78 (2002) 286-287
13. Miltiadous G., Anthopoulou A., and Elisaf M. Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy. JOP 4 (2003) 20-21
14. Tysk C., Al-Eryani A.Y., and Shawabkeh A.A. Acute pancreatitis induced by fluvastatin therapy. J Clin Gastroenterol 35 (2002) 406-408
15. Pezzilli R., Ceciliato R., Corinaldesi R., and Barakat B. Acute pancreatitis due to simvastatin therapy: increased severity after rechallenge. Dig Liver Dis 36 (2004) 639-640
16. Johnson J.L., and Loomis I.B. A case of simvastatin-associated pancreatitis and review of statin-associated pancreatitis. Pharmacotherapy 26 (2006) 414-422
17. Singh S., Nautiyal A., and Dolan J.G. Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect?. JOP 5 (2004) 502-504
18. Lons T., and Chousterman M. Simvastatin: a new drug responsible for acute pancreatitis?. Gastroenterol Clin Biol 15 (1991) 93-94 [in French]
19. Belaiche G., Ley G., and Slama J.L. Acute pancreatitis associated with atorvastatin therapy. Gastroenterol Clin Biol 24 (2000) 471-472 [in French]
20. Singh S. Drug induced pancreatitis might be a class effect of statin drugs. JOP 6 (2005) 380
21. Anagnostopoulos G.K., Tsiakos S., Margantinis G., Kostopoulos P., and Arvanitidis D. Acute pancreatitis due to pravastatin therapy. JOP 4 (2003) 129-132
22. Thisted H., Jacobsen J., Munk E.M., et al. Statins and the risk of acute pancreatitis: a population-based case-control study. Aliment Pharmacol Ther 23 (2006) 185-190
23. Segal A.S. Alopecia associated with atorvastatin. Am J Med 113 (2002) 171
24. Krasovec M., Elsner P., and Burg G. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Dermatology 186 (1993) 248-252
25. Mehregan D.R., Mehregan D.A., and Pakideh S. Cheilitis due to treatment with simvastatin. Cutis 62 (1998) 197-198
26. Pua V.S., Scolyer R.A., and Barnetson R.S. Pravastatin-induced lichenoid drug eruption. Australas J Dermatol 47 (2006) 57-59
27. Adcock B.B., Hornsby L.B., and Jenkins K. Dermographism: an adverse effect of atorvastatin. J Am Board Fam Pract 14 (2001) 148-151
28. Anliker M.D., and Wuthrich B. Chronic urticaria to atorvastatin. Allergy 57 (2002) 366
29. Pfeiffer C.M., Kazenoff S., and Rothberg H.D. Toxic epidermal necrolysis from atorvastatin. JAMA 279 (1998) 1613-1614
30. Gerson R.J., MacDonald J.S., Alberts A.W., et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res 50 (1990) 65-78
31. Adamska-Dyniewska H., Chojnowska-Jezierska J., Cybulska B., et al. Lovastatin in the treatment of hypercholesterolemia. Pol Arch Med Wewn 92 (1994) 54-62 [in Polish]
32. Bousquet E., Amar J., Salvador M., and Chamontin B. Cataract and simvastatin: case report. Therapie 53 (1998) 505-507 [in French]
33. Schlienger R.G., Haefeli W.E., Jick H., and Meier C.R. Risk of cataract in patients treated with statins. Arch Intern Med 161 (2001) 2021-2026
34. Smeeth L., Hubbard R., and Fletcher A.E. Cataract and the use of statins: a case-control study. QJM 96 (2003) 337-343
35. Klein B.E., Klein R., Lee K.E., and Grady L.M. Statin use and incident nuclear cataract. JAMA 295 (2006) 2752-2758
36. Fraunfelder F.W. Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors. J Ocul Pharmacol Ther 20 (2004) 179-182
37. Bucca C., Marsico A., Panaro E., Bigo P., and Brussino L. Statins and nasal polyps. Ann Intern Med 142 (2005) 310-311
38. Muldoon M.F., Manuck S.B., and Matthews K.A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 301 (1990) 309-314
39. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
40. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
41. Muldoon M.F., Manuck S.B., Mendelsohn A.B., Kaplan J.R., and Belle S.H. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 322 (2001) 11-15
42. Keller S., and Frishman W.H. Neuropsychiatric effects of cardiovascular drug therapy. Cardiol Rev 11 (2003) 73-93
43. Stewart R.A., Sharples K.J., North F.M., et al. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Arch Intern Med 160 (2000) 3144-3152
44. Boumendil E., and Tubert-Bitter P. Depression-induced absenteeism in relation to antihyperlipidemic treatment: a study using GAZEL cohort data. Epidemiology 6 (1995) 322-325
45. Duits N., and Bos F.M. Depressive symptoms and cholesterol-lowering drugs. Lancet 341 (1993) 114
46. Rosenson R.S., and Goranson N.L. Lovastatin-associated sleep and mood disturbances. Am J Med 95 (1993) 548-549
47. Ehrenberg B.L., Lamon-Fava S., Corbett K.E., et al. Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects. Sleep 22 (1999) 117-121
48. Gregoor P.J. Atorvastatin may cause nightmares. BMJ 332 (2006) 950
49. Boriani G., Biffi M., Strocchi E., and Branzi A. Nightmares and sleep disturbances with simvastatin and metoprolol. Ann Pharmacother 35 (2001) 1292
50. Vgontzas A.N., Kales A., Bixler E.O., Manfredi R.L., and Tyson K.L. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther 50 (1991) 730-737
51. Roth T., Richardson G.R., Sullivan J.P., et al. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 15 (1992) 426-432
52. Orsi A., Sherman O., and Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 21 (2001) 767-769
53. King D.S., Wilburn A.J., Wofford M.R., et al. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 23 (2003) 1663-1667
54. Bollen E.L., Gaw A., and Buckley B.M. Statin therapy and the prevention of dementia. Arch Neurol 58 (2001) 1023-1024
55. Etminan M., Gill S., and Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 23 (2003) 726-730
56. Gurm H.S., and Hoogwerf B. The Heart Protection Study: high-risk patients benefit from statins, regardless of LDL-C level. Cleve Clin J Med 70 (2003) 991-997
57. Liberopoulos E.N., and Mikhailidis D.P. Could statins be useful in the treatment of patients with migraine?. Headache 46 (2006) 672-675
58. Ramsey C.S., and Snyder Q.C. Altitude-induced migraine headache secondary to pravastatin: case report. Aviat Space Environ Med 69 (1998) 603-606
59. Vollmer T., Key L., Durkalski V., et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 (2004) 1607-1608
60. Golomb B.A., Criqui M.H., White H.L., and Dimsdale J.E. The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Contr Clin Trials 25 (2004) 178-202
61. Ahmad S. Lovastatin and peripheral neuropathy. Am Heart J 130 (1995) 1321
62. Chong P.H., Boskovich A., Stevkovic N., and Bartt R.E. Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy 24 (2004) 1194-1203
63. Jeppesen U., Gaist D., Smith T., and Sindrup S.H. Statins and peripheral neuropathy. Eur J Clin Pharmacol 54 (1999) 835-838
64. Rajabally Y.A., Varakantam V., and Abbott R.J. Disorder resembling Guillain-Barre syndrome on initiation of statin therapy. Muscle Nerve 30 (2004) 663-666
65. Gaist D., Garcia Rodriguez L.A., Huerta C., Hallas J., and Sindrup S.H. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?. Eur J Clin Pharmacol 56 (2001) 931-933
66. Gaist D., Jeppesen U., Andersen M., et al. Statins and risk of polyneuropathy: a case-control study. Neurology 58 (2002) 1333-1337
67. Corrao G., Zambon A., Bertu L., et al. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases. J Epidemiol Commun Health 58 (2004) 1047-1051
68. Anderson J.L., Muhlestein J.B., Bair T.L., et al. Do statins increase the risk of idiopathic polyneuropathy?. Am J Cardiol 95 (2005) 1097-1099
69. Phan T., McLeod J.G., Pollard J.D., et al. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 58 (1995) 625-628
70. Rosch P.J. Peripheral neuropathy. Lancet 364 (2004) 1663-1664
71. Jackson G. Erectile dysfunction and cardiovascular disease. Int J Clin Pract 53 (1999) 363-368
72. Rizvi K., Hampson J.P., and Harvey J.N. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 19 (2002) 95-98
73. Bruckert E., Giral P., Heshmati H.M., and Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 21 (1996) 89-94
74. Halkin A., Lossos I.S., and Mevorach D. HMG-CoA reductase inhibitor-induced impotence. Ann Pharmacother 30 (1996) 192
75. de Graaf L., Brouwers A.H., and Diemont W.L. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?. Br J Clin Pharmacol 58 (2004) 326-328
76. Jay R.H., Sturley R.H., Stirling C., et al. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. Br J Clin Pharmacol 32 (1991) 417-422
77. Aerts J., Karmochkine M., and Raguin G. Gynecomastia due to pravastatin. Presse Med 28 (1999) 787 [in French]
78. Undas A., Brummel K.E., Musial J., Mann K.G., and Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 103 (2001) 2248-2253
79. Szczeklik A., Undas A., Musial J., et al. Antithrombotic actions of statins. Med Sci Monit 7 (2001) 1381-1385
80. Tsiara S., Elisaf M., and Mikhailidis D.P. Early vascular benefits of statin therapy. Curr Med Res Opin 19 (2003) 540-556
81. Liberopoulos E.N., Daskalopoulou S.S., and Mikhailidis D.P. Early statin therapy in patients with acute coronary syndrome. Hellenic J Cardiol 46 (2005) 5-8
82. Groneberg D.A., Barkhuizen A., and Jeha T. Simvastatin-induced thrombocytopenia. Am J Hematol 67 (2001) 277
83. McCarthy L.J., Porcu P., Fausel C.A., Sweeney C.J., and Danielson C.F. Thrombotic thrombocytopenic purpura and simvastatin. Lancet 352 (1998) 1284-1285
84. Koduri P.R. Simvastatin and thrombotic thrombocytopenic purpura. Lancet 352 (1998) 2020
85. Sundram F., Roberts P., Kennedy B., and Pavord S. Thrombotic thrombocytopenic purpura associated with statin treatment. Postgrad Med J 80 (2004) 551-552
86. Nikolsky E., Sadeghi H.M., Effron M.B., et al. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol 96 (2005) 474-481
87. Antons K.A., Williams C.D., Baker S.K., and Phillips P.S. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 119 (2006) 400-409
88. Agarwal R. Effects of statins on renal function. Am J Cardiol 97 (2006) 748-755
89. Vidt D.G., Cressman M.D., Harris S., Pears J.S., and Hutchinson H.G. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 102 (2004) 52-60
90. Kostapanos M, Milionis H, Gazi I, et al. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia. J Clin Pharmacology; in press.
91. Weber M.H., and Verwiebe R. Alpha 1-microglobulin (protein HC): features of a promising indicator of proximal tubular dysfunction. Eur J Clin Chem Clin Biochem 30 (1992) 683-691
92. Verhulst A., D'Haese P.C., and De Broe M.E. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol 15 (2004) 2249-2257
93. Sidaway J.E., Davidson R.G., McTaggart F., et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 15 (2004) 2258-2265
94. Agarwal R., and Curley T.M. The role of statins in chronic kidney disease. Am J Med Sci 330 (2005) 69-81
95. Tiwari A. An overview of statin-associated proteinuria. Drug Discov Today 11 (2006) 458-464
96. van Zyl-Smit R., Firth J.C., Duffield M., and Marais A.D. Renal tubular toxicity of HMG-CoA reductase inhibitors. Nephrol Dial Transplant 19 (2004) 3176-3179
97. Tonolo G., Ciccarese M., Brizzi P., et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 20 (1997) 1891-1895
98. Tonolo G., Melis M.G., Formato M., et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 30 (2000) 980-987
99. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57 (2004) 728-734
100. Liberopoulos E.N., Mikhailidis D.P., Athyros V.G., and Elisaf M.S. The effect of cholesterol-lowering treatment on renal function. Am J Kidney Dis 47 (2006) 561
101. Kakafika A., Liamis G., Elisaf M., and Mikhailidis D. Effect of atorvastatin on serum creatinine levels. Curr Med Res Opin 17 (2001) 230-231
102. Elisaf M., and Mikhailidis D.P. Statins and renal function. Angiology 53 (2002) 493-502
103. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
104. Tsouli S.G., Liberopoulos E.N., Athyros V.G., Mikhailidis D.P., and Elisaf M.S. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. Metabolism 55 (2006) 1293-1301
105. Athyros V.G., Elisaf M., Papageorgiou A.A., et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 43 (2004) 589-599
106. Kakafika A., Tsimihodimos V., and Elisaf M. Effect of atorvastatin on serum uric acid levels. Atherosclerosis 158 (2001) 255
107. Milionis H.J., Kakafika A.I., Tsouli S.G., et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 148 (2004) 635-640
108. Milionis H.J., Liberopoulos E.N., Achimastos A., Elisaf M.S., and Mikhailidis D.P. Statins: another class of antihypertensive agents?. J Hum Hypertens 20 (2006) 320-335
109. Hanson J., and Bossingham D. Lupus-like syndrome associated with simvastatin. Lancet 352 (1998) 1070
110. Noel B., and Panizzon R.G. Lupus-like syndrome associated with statin therapy. Dermatology 208 (2004) 276-277
111. Quiceno G.A., and Cush J.J. Iatrogenic rheumatic syndromes in the elderly. Clin Geriatr Med 21 (2005) 577-588 vii
112. Vasconcelos O.M., and Campbell W.W. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 30 (2004) 803-807
113. Giordano N., Senesi M., Mattii G., et al. Polymyositis associated with simvastatin. Lancet 349 (1997) 1600-1601
114. Pelli N., and Setti M. Atorvastatin as a trigger of autoimmune hepatitis. J Hepatol 40 (2004) 716
115. Wolters L.M., and Van Buuren H.R. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 17 (2005) 589-590
116. Liebhaber M.I., Wright R.S., Gelberg H.J., Dyer Z., and Kupperman J.L. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases. Chest 115 (1999) 886-889
117. Lantuejoul S., Brambilla E., Brambilla C., and Devouassoux G. Statin-induced fibrotic nonspecific interstitial pneumonia. Eur Respir J 19 (2002) 577-580
118. McCarey D.W., McInnes I.B., Madhok R., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363 (2004) 2015-2021
119. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
120. Bjerre L.M., and LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 110 (2001) 716-723
121. Poynter J.N., Gruber S.B., Higgins P.D., et al. Statins and the risk of colorectal cancer. N Engl J Med 352 (2005) 2184-2192
122. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., and White C.M. Statins and cancer risk: a meta-analysis. JAMA 295 (2006) 74-80